Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL FRIEDREICH ATAXIA DRUG INDUSTRY
2.1 Summary about Friedreich Ataxia Drug Industry
2.2 Friedreich Ataxia Drug Market Trends
2.2.1 Friedreich Ataxia Drug Production & Consumption Trends
2.2.2 Friedreich Ataxia Drug Demand Structure Trends
2.3 Friedreich Ataxia Drug Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 ADVM-063
4.2.2 AGIL-FA
4.2.3 BHV-4157
4.2.4 BVA-202
4.2.5 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Clinic
4.3.2 Hospital
4.3.3 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 ADVM-063
5.2.2 AGIL-FA
5.2.3 BHV-4157
5.2.4 BVA-202
5.2.5 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Clinic
5.3.2 Hospital
5.3.3 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 ADVM-063
6.2.2 AGIL-FA
6.2.3 BHV-4157
6.2.4 BVA-202
6.2.5 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Clinic
6.3.2 Hospital
6.3.3 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 ADVM-063
7.2.2 AGIL-FA
7.2.3 BHV-4157
7.2.4 BVA-202
7.2.5 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Clinic
7.3.2 Hospital
7.3.3 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 ADVM-063
8.2.2 AGIL-FA
8.2.3 BHV-4157
8.2.4 BVA-202
8.2.5 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Clinic
8.3.2 Hospital
8.3.3 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 ADVM-063
9.2.2 AGIL-FA
9.2.3 BHV-4157
9.2.4 BVA-202
9.2.5 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Clinic
9.3.2 Hospital
9.3.3 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Adverum Biotechnologies Inc
10.1.2 BioMarin Pharmaceutical Inc.
10.1.3 Biovista Inc.
10.1.4 Cardero Therapeutics Inc
10.1.5 Catabasis Pharmaceuticals, Inc.
10.1.6 Forward Pharma A/S
10.1.7 Ixchel Pharma LLC
10.1.8 Pfizer Inc
10.1.9 ProQR Therapeutics NV
10.1.10 RaNA Therapeutics Inc
10.1.11 Reata Pharmaceuticals Inc
10.1.12 Retrotope Inc
10.1.13 Shire Plc
10.1.14 STATegics Inc
10.1.15 Voyager Therapeutics Inc
10.2 Friedreich Ataxia Drug Sales Date of Major Players (2017-2020e)
10.2.1 Adverum Biotechnologies Inc
10.2.2 BioMarin Pharmaceutical Inc.
10.2.3 Biovista Inc.
10.2.4 Cardero Therapeutics Inc
10.2.5 Catabasis Pharmaceuticals, Inc.
10.2.6 Forward Pharma A/S
10.2.7 Ixchel Pharma LLC
10.2.8 Pfizer Inc
10.2.9 ProQR Therapeutics NV
10.2.10 RaNA Therapeutics Inc
10.2.11 Reata Pharmaceuticals Inc
10.2.12 Retrotope Inc
10.2.13 Shire Plc
10.2.14 STATegics Inc
10.2.15 Voyager Therapeutics Inc
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
